Abstract
Management of the stage IIIA (N2) patient remains one of the most controversial areas in thoracic oncology. The potential cur-ability of at least some of these patients has encourage the development of more complex, aggressive, and toxic multimodality treatment regimens.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 69-100 |
| Number of pages | 32 |
| Journal | Chest Surgery Clinics of North America |
| Volume | 11 |
| Issue number | 1 |
| State | Published - 2001 |
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine